$90 million cancer care center slated for Arizona

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Priya Jayachandran, MD, FACP, spoke about her new position at El Camino Health as well as her career as a breast oncologist.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD

sNDA Submitted to FDA for Venetoclax Plus Acalabrutinib in Untreated CLL

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

AMPLIFY trial results form the basis of the submission, with venetoclax/acalabrutinib showing a PFS advantage vs chemoimmunotherapy in patients with CLL.

Roman Fabbricatore

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

AMPLIFY trial results form the basis of the submission, with venetoclax/acalabrutinib showing a PFS advantage vs chemoimmunotherapy in patients with CLL.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD

July 21st 2025

FDA Accepts BLA, Grants Priority Review to Tab-Cel in EBV-Positive PTLD

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Following the lifting of a clinical hold, the FDA has again accepted the BLA for tabelecleucel in adult and pediatric patients with EBV-positive PTLD.

Tim Cortese

Singh to Advance Northwell’s Skin Cancer Program With Surgical Director Promotion

Following the lifting of a clinical hold, the FDA has again accepted the BLA for tabelecleucel in adult and pediatric patients with EBV-positive PTLD.

Breast Medical Oncologist Returns Home to Serve in Multidisciplinary Clinic

Bhuvanesh Singh, MD, has big plans for enhancing the skin cancer program at Northwell Health.

Related Content

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Priya Jayachandran, MD, FACP, spoke about her new position at El Camino Health as well as her career as a breast oncologist.

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD

sNDA Submitted to FDA for Venetoclax Plus Acalabrutinib in Untreated CLL

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Roman Fabbricatore

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

AMPLIFY trial results form the basis of the submission, with venetoclax/acalabrutinib showing a PFS advantage vs chemoimmunotherapy in patients with CLL.

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD

July 21st 2025

FDA Accepts BLA, Grants Priority Review to Tab-Cel in EBV-Positive PTLD

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Tim Cortese

Singh to Advance Northwell’s Skin Cancer Program With Surgical Director Promotion

Following the lifting of a clinical hold, the FDA has again accepted the BLA for tabelecleucel in adult and pediatric patients with EBV-positive PTLD.